Here’s an update from our business partner Janssen Biotech that JNJ-6372 in combination with Lazertinib (YH25448), a novel third-generation EGFR TKI for advanced NSCLC that Yuhan Corporation out-licensed to them in November 2018, received Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA).
– Article from Johnson & Johnsonhttps://lnkd.in/gFMri6P
– Article from BioSpacehttps://lnkd.in/gjNTGqh